Cargando…

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiraga, Maggie Kamila, Kuypers, Kim P. C., Uthaug, Malin Vedoy, Ramaekers, Johannes G., Mason, Natasha Leigh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300865/ https://www.ncbi.nlm.nih.gov/pubmed/35873251 http://dx.doi.org/10.3389/fpsyt.2022.883869

Ejemplares similares

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
por: Heuschkel, Kristin, et al.
Publicado: (2020)

Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being
por: Kiraga, Maggie K., et al.
Publicado: (2021)

A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence
por: Theunissen, Eef Lien, et al.
Publicado: (2022)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
por: Nayak, Sandeep M., et al.
Publicado: (2023)

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study
por: Ruffell, Simon G. D., et al.
Publicado: (2021)

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
por: Huang, Joyce, et al.
Publicado: (2022)

Psilocybin: From Serendipity to Credibility?
por: Rucker, James J., et al.
Publicado: (2021)

Corrigendum: Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study
por: Ruffell, Simon G. D., et al.
Publicado: (2023)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
por: Rootman, Joseph M., et al.
Publicado: (2022)

Unraveling the Mysteries of Mental Illness With Psilocybin
por: Sottile, Robert, et al.
Publicado: (2022)

Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
por: Haijen, Eline C. H. M., et al.
Publicado: (2023)

A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats
por: Uthaug, M. V., et al.
Publicado: (2021)

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
por: Rootman, Joseph M., et al.
Publicado: (2022)

Psilocybin and Mental Health–Don't Lose Control
por: Barnby, Joseph M., et al.
Publicado: (2018)

Therapeutic effect of psilocybin in addiction: A systematic review
por: van der Meer, Pim B., et al.
Publicado: (2023)

Therapeutic use of psilocybin: Practical considerations for dosing and administration
por: MacCallum, Caroline A., et al.
Publicado: (2022)

Spontaneous and deliberate creative cognition during and after psilocybin exposure
por: Mason, N. L., et al.
Publicado: (2021)

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
por: Irizarry, Ricardo, et al.
Publicado: (2022)

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
por: Brett, Jonathan, et al.
Publicado: (2023)

(1)H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
por: Vilca-Melendez, Sylvana, et al.
Publicado: (2021)

Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective
por: van Ruitenbeek, Peter, et al.
Publicado: (2023)

Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
por: Spriggs, Meg J., et al.
Publicado: (2021)

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
por: Jones, Grant, et al.
Publicado: (2023)

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
por: Smigielski, Lukasz, et al.
Publicado: (2019)

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
por: Mason, N. L., et al.
Publicado: (2020)

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
por: Uthaug, Malin Vedøy, et al.
Publicado: (2021)

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research
por: Tai, Sara J., et al.
Publicado: (2021)

Manic episode following psilocybin use in a man with bipolar II disorder: a case report
por: Halim, Haniya J., et al.
Publicado: (2023)

Internet-Delivered Cognitive Behavior Therapy as a Prequel to Face-To-Face Therapy for Depression and Anxiety: A Naturalistic Observation
por: Duffy, Daniel, et al.
Publicado: (2020)

COVID-19 pandemic’s impact on networks of depression and anxiety in naturalistic transdiagnostic sample of outpatients with non-psychotic mental illness
por: Kim, Shin Tae, et al.
Publicado: (2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
por: Heinzerling, Keith G., et al.
Publicado: (2023)

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States
por: Raison, Charles L., et al.
Publicado: (2022)

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
por: Uthaug, M. V., et al.
Publicado: (2019)

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems
por: Argento, Elena, et al.
Publicado: (2021)

Cannabis Use and Neuroadaptation: A Call for Δ(9)-Tetrahydrocannabinol Challenge Studies
por: Ramaekers, Johannes G., et al.
Publicado: (2022)

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
por: Reckweg, Johannes T., et al.
Publicado: (2022)

Risk Factor for Retreatment Episode on Admission Among TB Patients With Schizophrenia
por: Wang, Hai-Rong, et al.
Publicado: (2021)

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
por: de Vos, Cato M. H., et al.
Publicado: (2021)

Irritability Is Associated With Decreased Cortical Surface Area and Anxiety With Decreased Gyrification During Brain Development
por: Piguet, Camille, et al.
Publicado: (2021)

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
por: Hutten, Nadia R. P. W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ucdc7fvenvmvmihs2hnideffja